GlassScriptPhysician profile
David W Marden
NPI 1699778605
$1,406.42
in general payments reported to CMS, 2019-2025
16 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $117 · 2021: $203 · 2022: $368 · 2023: $186 · 2024: $61.48 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $394.13 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $379.43 | 2019-2023 | Myrbetriq |
| Mayne Pharma Commercial LLC | $220.55 | 2021-2025 | |
| Therapeuticsmd, INC. | $121.83 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $55.81 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $42.56 | 2022-2024 | Zepbound |
| Abbvie INC. | $34.74 | 2021-2023 | |
| Daiichi Sankyo INC. | $27.38 | 2025 | Injectafer |
| Hologic Sales and Service, LLC | $19.37 | 2025 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $19.09 | 2024 | |
| Merck Sharp & Dohme LLC | $18.88 | 2019 | |
| Ibsa Pharma INC. | $16.24 | 2022 | |
| Exeltis, USA INC. | $15.99 | 2021 | |
| Currax Pharmaceuticals LLC | $14.86 | 2025 | Contrave |
| Acella Pharmaceuticals, LLC | $14.12 | 2025 | NP Thyroid 60 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.